116 related articles for article (PubMed ID: 11547362)
1. Recombinant von Willebrand factor: preclinical development.
Plaimauer B; Schlokat U; Turecek PL; Mitterer A; Mundt W; Auer W; Pichler L; Gritsch H; Schwarz HP
Semin Thromb Hemost; 2001 Aug; 27(4):395-403. PubMed ID: 11547362
[TBL] [Abstract][Full Text] [Related]
2. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
3. Development of a plasma- and albumin-free recombinant von Willebrand factor.
Turecek PL; Mitterer A; Matthiessen HP; Gritsch H; Varadi K; Siekmann J; Schnecker K; Plaimauer B; Kaliwoda M; Purtscher M; Woehrer W; Mundt W; Muchitsch EM; Suiter T; Ewenstein B; Ehrlich HJ; Schwarz HP
Hamostaseologie; 2009 Oct; 29 Suppl 1():S32-8. PubMed ID: 19763356
[TBL] [Abstract][Full Text] [Related]
4. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
5. Molecular genetics of von Willebrand disease.
Mazurier C; Ribba AS; Gaucher C; Meyer D
Ann Genet; 1998; 41(1):34-43. PubMed ID: 9599650
[TBL] [Abstract][Full Text] [Related]
6. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
[TBL] [Abstract][Full Text] [Related]
7. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
Budde U; Metzner HJ; Müller HG
Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
[TBL] [Abstract][Full Text] [Related]
9. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
[TBL] [Abstract][Full Text] [Related]
10. von Willebrand factor contained in a high purity FVIII concentrate (Fanhdi) binds to platelet glycoproteins and supports platelet adhesion to subendothelium under flow conditions.
Rivera J; Escolar G; Casamiquela R; Bravo MI; Jorquera JI; Castillo R; Ordinas A; Vicente V
Haematologica; 1999 Jan; 84(1):5-11. PubMed ID: 10091386
[TBL] [Abstract][Full Text] [Related]
11. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
[TBL] [Abstract][Full Text] [Related]
12. Role of factor VIII-von Willebrand factor and fibronectin in the interaction of platelets in flowing blood with monomeric and fibrillar human collagen types I and III.
Houdijk WP; Sakariassen KS; Nievelstein PF; Sixma JJ
J Clin Invest; 1985 Feb; 75(2):531-40. PubMed ID: 3919060
[TBL] [Abstract][Full Text] [Related]
13. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
[TBL] [Abstract][Full Text] [Related]
14. Comparative study on collagen-binding enzyme-linked immunosorbent assay and ristocetin cofactor activity assays for detection of functional activity of von Willebrand factor.
Turecek PL; Siekmann J; Schwarz HP
Semin Thromb Hemost; 2002 Apr; 28(2):149-60. PubMed ID: 11992238
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two von Willebrand factor collagen-binding assays with different binding affinities for low, medium, and high multimers of von Willebrand factor.
Neugebauer BM; Goy C; Budek I; Seitz R
Semin Thromb Hemost; 2002 Apr; 28(2):139-48. PubMed ID: 11992237
[TBL] [Abstract][Full Text] [Related]
16. Structure and function of a recombinant von Willebrand factor drug candidate.
Turecek PL; Schrenk G; Rottensteiner H; Varadi K; Bevers E; Lenting P; Ilk N; Sleytr UB; Ehrlich HJ; Schwarz HP
Semin Thromb Hemost; 2010 Jul; 36(5):510-21. PubMed ID: 20635317
[TBL] [Abstract][Full Text] [Related]
17. Plasma collagen cofactor correlates with von Willebrand factor antigen and ristocetin cofactor but not with bleeding time.
Aihara M; Kimura A; Chiba Y; Yoshida Y
Thromb Haemost; 1988 Jun; 59(3):485-90. PubMed ID: 3142084
[TBL] [Abstract][Full Text] [Related]
18. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
[TBL] [Abstract][Full Text] [Related]
19. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
[TBL] [Abstract][Full Text] [Related]
20. von Willebrand factor contained in factor VIII concentrates of different purities supports platelet adhesion in blood samples from a heterogeneous group of patients with von Willebrand disease.
Escolar G; Carretero M; Magallón M; Quintana M; Arnau C; Castillo R; Aznar-Salatti J
Haematologica; 1998 Nov; 83(11):1009-14. PubMed ID: 9864923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
